Fact based stock research
Edwards Lifesciences (NYSE:EW)


Edwards Lifesciences stock research in summary

edwards.com


Edwards Lifesciences shares have a BUY rating. They are safely financed and show above average growth, but are bad value. We recommend buying and holding Edwards Lifesciences shares.


Latest Obermatt Ranks


Country USA
Industry Health Care Equipment
Index S&P 500, D.J. US Medical Equipment
Size class XX-Large

February 1, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: Edwards Lifesciences

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
1
1
4
4
STOCK GROWTH RANKS
83
81
67
67
STOCK SAFETY RANKS
43
41
95
95
COMBINED STOCK RANKS
34
19
67
67

Last update of Combined Rank: 1-Feb-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Edwards Lifesciences in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 1-Feb-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Edwards Lifesciences; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
51
74
88
88
PROFIT GROWTH
80
77
100
100
STOCK RETURNS
68
93
1
1
CONSOLIDATED RANK: GROWTH
83
81
67
67

Financial reporting date of Growth Rank: 30-Sep-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Edwards Lifesciences.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
81
82
90
90
REFINANCING
20
20
LIQUIDITY
3
1
95
95
CONSOLIDATED RANK: SAFETY
43
41
95
95

Financial reporting date of Safety Rank: 30-Sep-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Edwards Lifesciences and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Edwards Lifesciences from February 1, 2018.